Terms: = Lymphoma AND TNFRSF14, Q92956, 8764, ENSG00000157873, TR2, ATAR, LIGHTR, HVEM, HVEA AND Clinical Outcome
3 results:
1. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract] [Full Text] [Related]
2. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract] [Full Text] [Related]
3. Extranodal B Cell lymphoma with Prominent Spindle Cell Features Arising in Uterus and in Maxillary Sinus: Report of Two Cases and Literature Review.
Li Y; Cui W; Woodroof JM; Zhang D
Ann Clin Lab Sci; 2016; 46(2):213-8. PubMed ID: 27098631
[TBL] [Abstract] [Full Text] [Related]
